아메바증 시장 규모, 점유율 및 성장 분석 : 치료법별, 제형별, 유통경로별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Amebiasis Market size was valued at USD 382.50 Million in 2024 and is poised to grow from USD 400.55 Million in 2025 to USD 582.40 Million by 2033, growing at a CAGR of 4.72% during the forecast period (2026-2033).

The global amebiasis market encompasses diagnostics, therapeutics, and prevention methods targeting Entamoeba histolytica, a leading cause of diarrhea in underprivileged populations. Due to its serious health implications, including potential mortality, amebiasis imposes a considerable financial strain on healthcare systems struggling with sanitation issues. Recent years have seen a shift from traditional microscopy to advanced techniques like antigen detection and PCR, driven by heightened awareness of asymptomatic carriers and the need for prompt treatment access. Innovations such as point-of-care immunochromatographic kits in Southeast Asia have broadened testing reach, demonstrating technology's role in market expansion. Additionally, increased governmental investment in water, sanitation, and hygiene initiatives is boosting demand for diagnostic and therapeutic solutions, paving the way for the adoption of multiplex panels for comprehensive screening.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Amebiasis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Amebiasis Market Segments Analysis

Global amebiasis market is segmented by treatment, form, distribution, end-user and region. Based on treatment, the market is segmented into metronidazole, tinidazole, paromomycin and diloxanide furoate. Based on form, the market is segmented into oral and intravenous. Based on distribution, the market is segmented into hospital pharmacies, retail pharmacies and government health programs. Based on end-user, the market is segmented into hospitals, public health clinics and travel medicine clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Amebiasis Market

The growth of the global amebiasis market is significantly influenced by heightened public awareness surrounding the symptoms and transmission of the disease. This awareness encourages more individuals to seek medical attention promptly, facilitating early detection and treatment, which can reduce the severity of the illness and prevent complications. As healthcare professionals become more knowledgeable and inclusive of amebiasis in their differential diagnoses, there is an increase in the recognition of actual cases. Consequently, this uptick in diagnostic activity drives demand for diagnostic kits, antiparasitic medications, and related healthcare services, further bolstering the expansion of the amebiasis market worldwide.

Restraints in the Global Amebiasis Market

The global amebiasis market faces significant constraints due to the inadequate healthcare infrastructure prevalent in numerous low-income countries. This limitation hinders access to advanced amebiasis treatments, which are often unavailable. Consequently, these regions tend to rely on outdated and less effective therapy regimens, exacerbated by geographic and logistical challenges that disrupt consistent supply availability. Additionally, healthcare providers in these areas frequently lack the necessary training and resources to implement newer treatment protocols effectively. As a result of these obstacles, patient outcomes remain suboptimal, and there is minimal growth in the development of innovative therapies in many high-need regions globally.

Market Trends of the Global Amebiasis Market

The Global Amebiasis market is witnessing a significant transformation driven by the rapid adoption of point-of-care testing (POCT). This trend enhances diagnostic capabilities in both urban and rural emergency settings, allowing clinicians to quickly identify amebiasis and initiate treatment without relying heavily on central laboratories. As governments and NGOs prioritize decentralized healthcare solutions, the demand for user-friendly and stable diagnostic tools is rising. Manufacturers are responding by developing easy-to-use diagnostics that require minimal training and can function effectively in diverse climates. This shift not only improves patient access to timely treatment but also supports global health initiatives against amebiasis.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Amebiasis Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Metronidazole
• Tinidazole
• Paromomycin
• Diloxanide Furoate

Global Amebiasis Market Size by Form & CAGR (2026-2033)

• Market Overview
• Oral
• Intravenous

Global Amebiasis Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Government Health Programs

Global Amebiasis Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Public Health Clinics
• Travel Medicine Clinics

Global Amebiasis Market Size & CAGR (2026-2033)

• North America (Treatment, Form, Distribution, End-User)
  • US
  • Canada
• Europe (Treatment, Form, Distribution, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Form, Distribution, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Form, Distribution, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Form, Distribution, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan (Viatris)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cadila Healthcare (Zydus)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mankind Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Macleods Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Searle Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Square Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beximco Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Strides Pharma Science
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Indoco Remedies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alembic Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations